301096.SZ
百诚医药
SZSE · M 科研服务 · CN
CNY 48.20
−3.15%Aug 26, 2026, 10:24 UTC
Baicheng Pharmaceutical announced its 2026 first-half results: revenue of 304 million yuan, down 8.40% year-on-year; net profit attributable to shareholders of 1.5977 million yuan, down 48.43% year-on-year; and a plan not to distribute dividends or convert capital reserves.
Source:Aug 11, 2026, 09:17 UTC
Baicheng Pharmaceutical's subsidiary Zhejiang Saimei Pharmaceutical won a bid in the 12th national centralized drug procurement for its sitagliptin and metformin extended-release tablets.
Source:Jul 27, 2026, 08:08 UTC
Baicheng Pharmaceutical received clinical trial approval notice from the National Medical Products Administration for its self-developed innovative drug BIOS0635-048 tablets.
Source:Jul 17, 2026, 09:12 UTC
Baicheng Pharmaceutical's wholly-owned subsidiary Zhejiang Saimei Pharmaceutical Co., Ltd. received a drug registration certificate from the National Medical Products Administration for its class 2.2 modified new drug Levetiracetam Extended-Release Granules.
Jul 15, 2026, 01:41 UTC
Baicheng Pharmaceutical and others established a new medical technology company, Zhejiang Wusheng Medical Technology Co., Ltd.
Source: